AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 1 - (NewsRx.com & NewsRx.net) -- FibroGen, Inc., announced that FG-3019, the company's lead investigational antifibrotic agent, significantly improved glomerular filtration rate (a measure of kidney function) and reduced proteinuria (abnormal presence of protein in the urine) in a preclinical model of overt diabetic nephropathy (DN).
The data support the therapeutic potential of FG-3019 in treating DN by inhibiting fibrosis, or excessive and persistent scarring, which ultimately causes kidney failure.
FG-3019 is a fully human monoclonal antibody designed to inhibit the fibrotic activity of connective tissue growth factor (CTGF). These results were part of multiple abstracts evaluating the effect of FG-3019 and the pathological role of CTGF throughout the progression of DN presented by FibroGen and collaborators at Renal Week 2004, the annual meeting of the American Society of Nephrology, held in St. Louis, Missouri.
In a model of type 1 diabetes induced by streptozotocin, diabetic rats were subjected to a comparatively short renal ischemia of 30 minutes, which caused a progressive injury characterized by tubular atrophy, dilation of the remaining tubuli, pronounced infiltration of inflammatory cells, and tubulointerstitial fibrosis. The results demonstrated that treatment with FG-3019 improved kidney function and histopathology and reduced proteinuria, effects attributed, in part, to reduced fibrosis.
"The demonstrated ability of FG-3019 to improve kidney function in this preclinical model that resembles late-stage DN in humans reinforces the therapeutic concept that blocking fibrosis is key to improving clinical outcomes in overt kidney disease," said David Y. Liu, PhD, vice president of research at FibroGen.
A second study evaluated the effects of FG-3019 on key clinical manifestations of early-stage DN in db/db obese type 2 diabetic mice, characterized by ...